Literature DB >> 21956418

miR-191 down-regulation plays a role in thyroid follicular tumors through CDK6 targeting.

Marianna Colamaio1, Eleonora Borbone, Lucia Russo, Mimma Bianco, Antonella Federico, Daniela Califano, Gennaro Chiappetta, Pierlorenzo Pallante, Giancarlo Troncone, Sabrina Battista, Alfredo Fusco.   

Abstract

CONTEXT: Well-differentiated thyroid carcinomas include papillary (PTC) and follicular (FTC) carcinomas. FTC is usually a more aggressive form of cancer than the more common papillary type. miR-191 expression is frequently altered in several neoplasias, being up-regulated in some cases, such as pancreatic carcinomas, and down-regulated in other carcinomas, such as melanomas.
OBJECTIVE: The objective was to evaluate the expression and the role of miR-191 in thyroid carcinogenesis.
DESIGN: The expression of miR-191 was analyzed in tissues from patients with follicular adenoma (n = 24), FTC (n = 24), PTC (n = 15), anaplastic thyroid carcinoma (n = 8), and the follicular variant of PTC (n = 6) compared with normal thyroid tissues by quantitative RT-PCR. miR-191 expression was restored in the follicular thyroid cell line WRO, and the effects on cell proliferation, migration, and target expression were evaluated.
RESULTS: miR-191 is down-regulated in follicular adenoma, FTC, and follicular variant of PTC. We identified CDK6, a serine-threonine kinase involved in the control of cell cycle progression, as a novel target of miR-191. Restoration of miR-191 expression in WRO cells reduces cell growth and migration rate on vitronectin. CDK6 overexpression, correlated with miR-191 down-regulation, was found in follicular adenoma and FTC, suggesting a role of miR-191 down-regulation in the generation of these neoplasias.
CONCLUSIONS: Our results suggest that miR-191 down-regulation plays a role in thyroid neoplasias of the follicular histotype, likely by targeting CDK6.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21956418     DOI: 10.1210/jc.2011-0408

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

Review 1.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

2.  miRNA expression profiling of 'noninvasive follicular thyroid neoplasms with papillary-like nuclear features' compared with adenomas and infiltrative follicular variants of papillary thyroid carcinomas.

Authors:  Nicla Borrelli; Maria Denaro; Clara Ugolini; Anello Marcello Poma; Mario Miccoli; Paolo Vitti; Paolo Miccoli; Fulvio Basolo
Journal:  Mod Pathol       Date:  2016-09-02       Impact factor: 7.842

Review 3.  Noncoding RNAs in endocrine malignancy.

Authors:  Jessica Kentwell; Justin S Gundara; Stan B Sidhu
Journal:  Oncologist       Date:  2014-04-09

4.  Hypoxia-induced microRNA-191 contributes to hepatic ischemia/reperfusion injury through the ZONAB/Cyclin D1 axis.

Authors:  Wenming Pan; Lin Wang; Xiao-Fei Zhang; Hongji Zhang; Jinxiang Zhang; Guoliang Wang; Peng Xu; Yunwei Zhang; Ping Hu; Xiao-Dong Zhang; Run-Lei Du; Hui Wang
Journal:  Cell Death Differ       Date:  2018-05-16       Impact factor: 15.828

Review 5.  Deregulation of microRNA expression in thyroid tumors.

Authors:  Zi-ming Yuan; Zhi-li Yang; Qi Zheng
Journal:  J Zhejiang Univ Sci B       Date:  2014-03       Impact factor: 3.066

Review 6.  The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies.

Authors:  S Pishkari; M Paryan; M Hashemi; E Baldini; S Mohammadi-Yeganeh
Journal:  J Endocrinol Invest       Date:  2017-07-31       Impact factor: 4.256

7.  MicroRNA-191 promotes pancreatic cancer progression by targeting USP10.

Authors:  Hua Liu; Xuan-Fu Xu; Yan Zhao; Mao-Chun Tang; Ying-Qun Zhou; Jie Lu; Feng-Hou Gao
Journal:  Tumour Biol       Date:  2014-08-29

8.  Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status.

Authors:  Gianpiero Di Leva; Claudia Piovan; Pierluigi Gasparini; Apollinaire Ngankeu; Cristian Taccioli; Daniel Briskin; Douglas G Cheung; Brad Bolon; Laura Anderlucci; Hansjuerg Alder; Gerard Nuovo; Meng Li; Marilena V Iorio; Marco Galasso; Ramasamy Santhanam; Santhanam Ramasamy; Guido Marcucci; Danilo Perrotti; Kimerly A Powell; Anna Bratasz; Michela Garofalo; Kenneth P Nephew; Carlo M Croce
Journal:  PLoS Genet       Date:  2013-03-07       Impact factor: 5.917

9.  XB130, a new adaptor protein, regulates expression of tumor suppressive microRNAs in cancer cells.

Authors:  Hiroki Takeshita; Atsushi Shiozaki; Xiao-Hui Bai; Daisuke Iitaka; Hyunhee Kim; Burton B Yang; Shaf Keshavjee; Mingyao Liu
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

10.  Association between the rs2910164 polymorphism in pre-Mir-146a sequence and thyroid carcinogenesis.

Authors:  Wen-Jun Wei; Yu-Long Wang; Duan-Shu Li; Yu Wang; Xiao-Feng Wang; Yong-Xue Zhu; Ya-Jun Yang; Zhuo-Ying Wang; Yan-Yun Ma; Yi Wu; Li Jin; Qing-Hai Ji; Jiu-Cun Wang
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.